Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.36 |
| ▸ | OGG1 | O15527 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749574 | 0.79 | HDAC4 (0.38) | ALOX15TSHRCYP2D6CYP3A4PORCN | |
| SCHEMBL13044519 | 0.72 | GABRG2 (0.40) | KDM4EALOX15CYP2D6CYP2C9CYP3A4 | |
| SCHEMBL3745747 | 0.71 | MEN1 (0.36) | KDM4EHPGDTSHRCYP2C9CYP1A2 | |
| SCHEMBL3745029 | 0.70 | RIPK1 (0.36) | KDM4EHPGDTSHRCYP19A1ALDH1A1 | |
| SCHEMBL3750045 | 0.66 | MAPT (0.39) | ALOX15TSHRCYP3A4CYP1A2CYP19A1 | |
| SCHEMBL3746753 | 0.66 | MAOB (0.36) | KDM4ECYP19A1 | |
| SCHEMBL7005980 | 0.65 | CYP3A4 (0.69) | NOS2ALOX15TSHRCYP2D6CYP2C9 | |
| SCHEMBL3747326 | 0.65 | CYP3A4 (0.37) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL10512975 | 0.62 | LMNA (0.62) | ALOX15TSHRCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL8485356 | 0.62 | MAPT (0.60) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | claimed |
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | BACE1, APP, BACE2 | NOS2 2280/4885KDM4E 4470/4885USP2 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.